RAPT Therapeutics Income Statement (2020-2024) | RAPT

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024
Revenue & cost
Revenue 0.94M1.28M1.53M1.30M1.22M0.87M0.97M0.76M0.64M0.89M
Operating items
Research & Development 10.68M10.99M12.91M10.90M13.77M13.19M15.72M14.30M16.67M14.36M16.60M19.45M25.57M21.64M27.02M26.76M
Selling, General & Administrative 3.29M2.80M3.20M3.48M4.01M3.76M3.77M4.49M4.75M5.44M5.08M4.98M5.99M6.72M6.90M6.45M
Operating Expenses 13.97M13.79M16.11M14.39M17.78M16.95M19.50M18.79M21.42M19.80M21.68M24.43M31.56M28.36M33.92M33.22M
Operating Income -13.04M-12.51M-14.58M-13.09M-16.56M-16.08M-18.53M-18.03M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
EBIT -13.04M-12.51M-14.58M-13.09M-16.56M-16.08M-18.53M-18.03M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
Non-operating items
Non Operating Income 0.14M0.39M0.24M0.55M0.05M-0.03M-0.12M0.10M0.31M-0.28M0.44M1.48M2.29M3.08M2.55M2.34M
Net income details
EBT -12.90M-12.12M-14.34M-12.54M-16.51M-16.11M-18.65M-17.93M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
Tax Provisions 0.24M0.27M0.29M0.20M
Profit After Tax -13.14M-12.39M-14.63M-12.73M-16.51M-16.11M-18.65M-17.93M-20.47M-19.18M-21.23M-22.95M-29.27M-25.28M-31.37M-30.88M
Income from Continuing Operations -13.14M-12.39M-14.63M-12.73M-16.51M-16.11M-18.65M-17.93M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
Consolidated Net Income -13.14M-12.39M-14.63M-12.73M-16.51M-16.11M-18.65M-17.93M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
Income towards Parent Company -13.14M-12.39M-14.63M-12.73M-16.51M-16.11M-18.65M-17.93M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
Net Income towards Common Stockholders -13.14M-12.39M-14.63M-12.73M-16.51M-16.11M-18.65M-17.93M-20.78M-18.91M-21.68M-24.43M-31.56M-28.36M-33.92M-33.22M
Additional items
EPS (Basic) -0.56-0.51-0.60-0.52-0.66-0.63-0.63-0.61-0.69-0.62-0.63-0.65-0.76-0.66-0.82-0.81
EPS (Weighted Average and Diluted) -0.66-0.63-0.61-0.69-0.62-0.63-0.65-0.76-0.66-0.82-0.81
Shares Outstanding (Weighted Average) 3.04M3.05M3.06M3.07M3.11M3.13M3.69M3.69M3.70M3.71M3.71M3.74M4.29M4.29M4.29M4.30M4.35M4.36M4.36M
Shares Outstanding (Diluted Average) 25.59M29.49M27.39M29.57M31.14M33.68M32.54M38.28M38.33M38.36M38.34M38.63M38.87M38.90M
EBITDA -13.15M-12.22M-14.73M-12.99M-16.53M-16.06M-18.47M-18.18M-21.38M-18.81M-20.94M-22.52M-28.91M-25.80M-31.31M-30.65M